TNF and Crohn disease: Another retrospective study conducted in patients with RA or Crohn’s disease and T2D who received anti-TNF agents (infliximab or etanercept) in larger therapeutic doses for up to 10 years found that initiation of anti-TNF treatment was associated with a significant improvement in fasting blood glucose, HbA1c (on average −1.0%), and triglyceride values [148].